Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;42(7):608-13.
doi: 10.1038/ng.604. Epub 2010 Jun 6.

Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists

Andrew D Johnson  1 , Lisa R Yanek, Ming-Huei Chen, Nauder Faraday, Martin G Larson, Geoffrey Tofler, Shiow J Lin, Aldi T Kraja, Michael A Province, Qiong Yang, Diane M Becker, Christopher J O'Donnell, Lewis C Becker
Affiliations

Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists

Andrew D Johnson et al. Nat Genet. 2010 Jul.

Abstract

Platelet function mediates both beneficial and harmful effects on human health, but few genes are known to contribute to variability in this process. We tested association of 2.5 million SNPs with platelet aggregation responses to three agonists (ADP, epinephrine and collagen) in two cohorts of European ancestry (N<or=2,753 in the Framingham Heart Study, N<or=1,238 in the Genetic Study of Atherosclerosis Risk). We identified associations of seven loci with platelet aggregation near or within GP6 (P=4.6x10(-13)), PEAR1 (P=3.4x10(-12)), ADRA2A (P=3.3x10(-11)), PIK3CG (P=3.1x10(-9)), JMJD1C (P=1.6x10(-8)), MRVI1 (P=2.0x10(-8)) and SHH (P=4.5x10(-8)). Six of these loci replicated at P<0.05 in an additional African-American cohort (N<or=840 in the Genetic Study of Atherosclerosis Risk). These results provide insights into platelet aggregation pathways and may suggest new antiplatelet therapeutic targets.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
See this image and copyright information in PMC

References

    1. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2009;150:405–410. - PubMed
    1. Quinn MJ, Topol EJ. Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics. 2001;2:341–352. - PubMed
    1. Faraday N, Becker DM, Becker LC. Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics. 2007;8:1413–1425. - PubMed
    1. O’Donnell CJ, et al. Genetic and environmental contributions to platelet aggregation: the Framingham Heart Study. Circ. 2001;103:3051–3056. - PubMed
    1. Bray PF, et al. Heritability of platelet function in families with premature coronary artery disease. J. Thromb. Haemo. 2007;5:1617–1623. - PubMed

Publication types